ILM1 Stock Chart & Stats
CHF11.71
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF11.71
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF9.50 - CHF11.83
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF246.16M
Enterprise ValueCHF412.89
Total Cash (Recent Filing)CHF83.16M
Total Debt (Recent Filing)CHF200.02M
Price to Earnings (P/E)22.9
Beta1.96
Next Earnings
Nov 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding25,505,724
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)0.71
Price to Sales (P/S)0.17
P/FCF Ratio9.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF19.89Price Target Upside69.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)1.22
Revenue Forecast (FY)CHF1.99B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe exceptional top-line expansion indicates strong demand for specialty-pharmaceutical distribution and patient-specific therapy services. Sustained growth can improve scale, deepen pharmacy relationships, and create operating leverage if profitability improves.
Positive Free Cash FlowPositive free cash flow and reasonable conversion to earnings provide internal funding for operations and investment. This reduces reliance on external financing and supports resilience, although the recent decline in cash generation remains a constraint.
Manageable Balance Sheet LeverageThe substantial equity base and moderate debt-to-equity ratio provide financial capacity to support specialty-pharma operations. This balance-sheet foundation can help the company absorb volatility and fund growth without excessive dependence on new borrowing.
Bears Say
Very Thin ProfitabilityThin margins leave limited protection against supplier costs, pricing pressure, operating expenses, or unfavorable product mix. Even substantial revenue growth may therefore produce only modest earnings, constraining reinvestment and increasing earnings sensitivity.
Weakening Cash GenerationThe sharp reduction in free cash flow signals weaker cash conversion despite positive absolute cash generation. If this persists, internally funded expansion may become harder and the company could need more working-capital financing or debt.
Rising Debt And Modest ReturnsAlthough current leverage is manageable, the upward debt trajectory increases financial risk if earnings weaken. The low return on equity also indicates limited profitability from invested capital, potentially reducing the efficiency of future balance-sheet expansion.
Medios AG News
ILM1 FAQ
What was Medios AG’s price range in the past 12 months?
Medios AG lowest stock price was CHF9.50 and its highest was CHF11.83 in the past 12 months.
What is Medios AG’s market cap?
Medios AG’s market cap is CHF246.16M.
When is Medios AG’s upcoming earnings report date?
Medios AG’s upcoming earnings report date is Nov 10, 2026 which is in 54 days.
How were Medios AG’s earnings last quarter?
Medios AG released its earnings results on Aug 12, 2026. The company reported CHF0.137 earnings per share for the quarter.
Is Medios AG overvalued?
According to Wall Street analysts Medios AG’s price is currently Undervalued.
Does Medios AG pay dividends?
Medios AG does not currently pay dividends.
What is Medios AG’s EPS estimate?
Medios AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medios AG have?
Medios AG has 25,505,724 shares outstanding.
What happened to Medios AG’s price movement after its last earnings report?
Medios AG reported an EPS of CHF0.137 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medios AG?
Currently, no hedge funds are holding shares in CH:ILM1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medios AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF19.89 (69.84% Upside)
CHF19.89 (69.84% Upside)
Insider Transactions
Bought Shares
Worth CHF36.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment also includes cytostatic preparations, antibody therapies, and parenteral nutrition solutions. The International Business International covers all activities in the international environment from the procurement of Active Pharmaceutical Ingredients, the sterile and non-sterile drugs and the supply of public and hospital pharmacies through homecare service. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. Medios AG is founded in 2015 and was headquartered in Berlin, Germany.
ILM1 Company Deck
ILM1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance and strategic advancements, despite some challenges in specific segments and increased costs related to acquisitions.View all CH:ILM1 earnings summariesILM1 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
CHF19.89
▲(69.84% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
MATERNUS-Kliniken AG
―
Limes Schlosskliniken AG
―
Eifelhoehen-Klinik AG
―
Gesundheitswelt Chiemgau AG
―
M1 Kliniken AG
―





